Hambek M - Search Results

1

Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.

Balermpas P, Keller C, Hambek M, Wagenblast J, Seitz O, Rödel C, Weiss C. Balermpas P, et al. Among authors: hambek m. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e377-83. doi: 10.1016/j.ijrobp.2011.12.088. Epub 2012 Mar 11. Int J Radiat Oncol Biol Phys. 2012. PMID: 22414284

2

A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).

Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R. Baghi M, et al. Among authors: hambek m. Anticancer Res. 2006 Jan-Feb;26(1B):585-90. Anticancer Res. 2006. PMID: 16739325 Free article. Clinical Trial.

3

Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.

Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, Ackermann H, May A, Hambek M, Knecht R. Wagenblast J, et al. Among authors: hambek m. J Cancer Res Clin Oncol. 2009 Mar;135(3):387-93. doi: 10.1007/s00432-008-0477-0. Epub 2008 Oct 1. J Cancer Res Clin Oncol. 2009. PMID: 18830627

4

Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?

Wagenblast J, Baghi M, Mörtel S, Hirth D, Thron L, Arnoldner C, Gstöttner W, May A, Hambek M. Wagenblast J, et al. Among authors: hambek m. Oncol Rep. 2009 Jul;22(1):171-6. doi: 10.3892/or_00000421. Oncol Rep. 2009. PMID: 19513520

5

Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.

Balermpas P, Hambek M, Seitz O, Rödel C, Weiss C. Balermpas P, et al. Among authors: hambek m. Strahlenther Onkol. 2009 Dec;185(12):775-81. doi: 10.1007/s00066-009-2092-7. Strahlenther Onkol. 2009. PMID: 20013086

6

Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.

Baghi M, Mack MG, Hambek M, Bisdas S, Muerthel R, Wagenblast J, Gstoettner W, Vogl T, Knecht R. Baghi M, et al. Among authors: hambek m. Head Neck. 2007 Feb;29(2):104-8. doi: 10.1002/hed.20488. Head Neck. 2007. PMID: 17111434

7

Inverse correlation between serum PGE2 and T classification in head and neck cancer.

Hambek M, Baghi M, Wagenblast J, Schmitt J, Baumann H, Knecht R. Hambek M, et al. Head Neck. 2007 Mar;29(3):244-8. doi: 10.1002/hed.20503. Head Neck. 2007. PMID: 17123309

8

Demands on caring relatives of head and neck cancer patients.

Baghi M, Wagenblast J, Hambek M, Radeloff A, Gstoettner W, Scherzed A, Spaenkuch B, Yuan J, Hornung S, Strebhardt K, Knecht R. Baghi M, et al. Among authors: hambek m. Laryngoscope. 2007 Apr;117(4):712-6. doi: 10.1097/mlg.0b013e318031d0b4. Laryngoscope. 2007. PMID: 17415143

9

Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.

Wagenblast J, Hambek M, Baghi M, Gstöttner W, Strebhardt K, Ackermann H, Knecht R. Wagenblast J, et al. Among authors: hambek m. J Cancer Res Clin Oncol. 2008 Mar;134(3):323-30. doi: 10.1007/s00432-007-0287-9. Epub 2007 Aug 14. J Cancer Res Clin Oncol. 2008. PMID: 17701215

10

Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.

Wagenblast J, Hambek M, Baghi M, Knecht R. Wagenblast J, et al. Among authors: hambek m. Anticancer Res. 2008 Mar-Apr;28(2A):687-92. Anticancer Res. 2008. PMID: 18507008 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters